IP Verse

Methods Of Treating Fabry Patients Having Renal Impairment

Patent No. EP3630114 (titled "Methods Of Treating Fabry Patients Having Renal Impairment") was filed by Amicus Therapeutics on May 30, 2018. The application was issued on Nov 1, 2023.

Patent Summary

Migalastat improves renal function and reduces proteinuria in Fabry patients with renal impairment by stabilizing renal function, reducing left ventricular mass index, and increasing α-Gal A activity in the patient. The treatment involves administering migalastat at a frequency of once every other day, with dosages ranging from 100 mg to 150 mg. This approach enables therapeutic levels of migalastat to be maintained in patients with impaired renal function, where conventional ERT may not be effective.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSJul 31, 2024D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3630114

AMICUS THERAPEUTICS
Application Number
EP18733415A
Filing Date
May 30, 2018
Status
Granted And Under Opposition
Sep 29, 2023
Publication Date
Nov 1, 2023
External Links
Slate, Register , Google Patents